Comparing UC treatments: infliximab vs ustekinumab vs both
Treatments studied
Part of Digestive system clinical trials.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have moderate to severe ulcerative colitis (UC) that hasn't responded well to standard treatments like steroids or immune-suppressing drugs, or you couldn't take them.
- You have not previously taken infliximab (Remicade) or ustekinumab (Stelara) for UC.
- You are willing to use effective birth control (if you could become pregnant) during the study and for 6 months after the last dose.
- You do not have active tuberculosis, HIV, hepatitis B or C, or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study compares two biologic medicines, vedolizumab and infliximab, to see which works better for children with moderate to severe ulcerative colitis. It aims to find a more effective treatment to reduce symptoms and improve quality of life.
This trial tests three different types of biologic medications to find which works best as a first treatment for moderate-to-severe ulcerative colitis.
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study compares two biologic medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. The goal is to reduce inflammation and help you feel better.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.